Although ERBB2 amplification/HER2 overexpression is a clear target for anti-HER2 therapy in advanced breast and gastroesophageal cancers, there is no officially approved therapy for patients with advanced NSCLC with ERBB2 amplification/HER2 overexpression. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.